KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) EBIAT (2017 - 2025)

Amneal Pharmaceuticals has reported EBIAT over the past 9 years, most recently at $35.1 million for Q4 2025.

  • Quarterly results put EBIAT at $35.1 million for Q4 2025, up 194.04% from a year ago — trailing twelve months through Dec 2025 was $85.2 million (up 215.4% YoY), and the annual figure for FY2025 was $72.1 million, up 197.54%.
  • EBIAT for Q4 2025 was $35.1 million at Amneal Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Over the last five years, EBIAT for AMRX hit a ceiling of $35.6 million in Q2 2025 and a floor of -$242.1 million in Q2 2022.
  • Median EBIAT over the past 5 years was $3.1 million (2022), compared with a mean of -$17.4 million.
  • Biggest five-year swings in EBIAT: crashed 3512.44% in 2023 and later skyrocketed 1618.59% in 2025.
  • Amneal Pharmaceuticals' EBIAT stood at -$27.5 million in 2021, then soared by 113.72% to $3.8 million in 2022, then crashed by 3512.44% to -$128.6 million in 2023, then soared by 109.27% to $11.9 million in 2024, then skyrocketed by 194.04% to $35.1 million in 2025.
  • The last three reported values for EBIAT were $35.1 million (Q4 2025), $2.4 million (Q3 2025), and $35.6 million (Q2 2025) per Business Quant data.